Drug
Dacomitinib clinical trials
Also written PF-00299804 and Vizimpro.
Keep track of what changes. Save the dacomitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
46 studies that test it; most in 2008 (7)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 7 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 3 |
| 2020 | 7 |
| 2021 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 25
Pfizer (21) · Shanghai Chest Hospital (2) · National Cancer Centre, Singapore (2) · The Netherlands Cancer Institute (2) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · University Health Network, Toronto (2) · Memorial Sloan Kettering Cancer Center (1) · NCIC Clinical Trials Group (1)
Often tested with
Tested in the same studies.
Crizotinib (4) · Osimertinib (3) · Afatinib (3) · Palbociclib (3) · Vemurafenib (3) · Alectinib (2) · Imatinib (2) · Olaparib (2)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses dacomitinib is read from its arms, and is right about nine times in ten.
Testing it · 46
- EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyRecruitingPhase 3Region SkaneNCT06486142Written as Afatinib/Dacomitinib
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04423185Written as Dacomitinib 45 MG
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Dacomitinib
- First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R MutationsRecruitingPhase 1/2Shanghai Chest HospitalNCT05271916Written as Dacomitinib+Anlotinib
- Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung CancerCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03810807Written as Dacomitinib
- Dacomitinib in Lung Cancer With Uncommon EGFR MutationsActive, not recruitingPhase 2Shanghai Chest HospitalNCT04504071Written as Dacomitinib
- Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLCCompletedPhase 1/2The Netherlands Cancer InstituteNCT02039336Written as Dacomitinib
- Phase 2 Study of Dacomitinib in NSCLCActive, not recruitingPhase 2National Cancer Centre, SingaporeNCT04027647Written as Dacomitinib
- Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging BiomarkersActive, not recruitingPhase 2National Cancer Centre, SingaporeNCT04946968Written as Oral Dacomitinib
- A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 WeeksCompletedPhase 1PfizerNCT00728390Written as PF-00299804
- Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating MutationsCompletedPhase 4PfizerNCT04511533Written as Dacomitinib
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524Written as Dacomitinib
- ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.CompletedPhase 3PfizerNCT01774721Written as Dacomitinib (PF-00299804)
- PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic CancerCompletedPhase 3NCIC Clinical Trials GroupNCT01000025Written as PF-00299804
- Best EGFR-TKI Sequence in NSCLC Harboring EGFR MutationsStatus unknownPhase 2Fondazione Ricerca TraslazionaleNCT04811001Written as Dacomitinib
- Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.CompletedPhase 2Grupo Español de Investigación en NeurooncologíaNCT01520870Written as PF-299804 (Dacomitinib)
- Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the PenisCompletedPhase 2Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT01728233Written as Dacomitinib
- Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell CancerCompletedPhase 2PfizerNCT00768664Written as PF-00299804
- Central Nervous System(CNS) Efficacy of DacomitinibStatus unknownPhase 2Samsung Medical CenterNCT04675008Written as Dacomitinib
- Evaluate Severe Hepatic Impairment on Dacomitinib PKCompletedPhase 1PfizerNCT03865446Written as Dacomitinib
See all 46 studies that test dacomitinib →
Given in every arm · 4 — dacomitinib is usual care beside what is tested
- A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.CompletedEarly Phase 1Memorial Sloan Kettering Cancer CenterNCT03755102Written as Dacomitinib
- A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)CompletedPhase 1PfizerNCT01920061Written as Dacomitinib
- Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PROCompletedPhase 2PfizerNCT01465802Written as Dacomitinib
- Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and NeckCompletedPhase 1University Health Network, TorontoNCT01737008Written as dacomitinib
Codes
What other systems call dacomitinib · ClinicalTrials.gg INT005210
- MeSH (NLM) C525726dacomitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5092U85G58DACOMITINIBConfirmed FDA, NLM
- RxNorm 2058849One source FDA
- NCI Thesaurus C53398DacomitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C525726 | dacomitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5092U85G58 | DACOMITINIB | Confirmed FDA, NLM |
| RxNorm | 2058849 | — | One source FDA |
| NCI Thesaurus | C53398 | Dacomitinib | One source FDA |
Also registered as dacomitinib anhydrous (UNII 2XJX250C20).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.